SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Hepatitis B/C and NASH: Crossroads Between Science and Business (not available)- Geoffrey MeachamView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Real-world utilization and effectiveness of elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada: Z-PROFILE study (not yet available)- Dr. E. TamView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Elucidating the structural and dynamic mechanism of resistance for clinically relevant variants against HCV NS3/4A protease inhibitors (not available)- Dr. A. MatthewView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Short Duration DAA HCV Therapy: How Short Can We Go?- Shyam Kottilil, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017The Global Burden of Non-alcoholic Steatohepatitis (not available)- Zobair YounossiView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017A Tale of Two Viruses: HBV and HCV Co-infection (not available)- Jake LiangView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Liver Disease in Chinese-perspective from a Hepatologist- George Lau, MBBS, MRCP, FHKCP, FHKAM, MD, FRCPView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017DAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination- Jason GrebelyView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Access to HIV, HBV, and HCV Antiviral Agents Globally- John Martin, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Novel Nucleosides, CMCP and CFCP, Potently Block the Infectivity and Replication of Wild-type and Drug-resistant HBVs in Culture and in Human-liver-chimeric Mice and Show Potential QW or Q2W (not available)- Dr. H. MitsuyaView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017The French and European Approach Towards Hepatitis Elimination- Tarik Asselah, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drugs (PWID) in the United States (US): a mathematical model using data from the C-EDGE CO-STAR Study- Dr. M. RobertsonView Slideset
